Trial · NCT00098813
Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
NCT00098813, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2013-12-19
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine. Trials, record NCT00098813. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00098813
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
- NCT number
- NCT00098813
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 20 participants, actual
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
- Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer
- Interventions
- romidepsin, laboratory biomarker analysis, positron emission tomography
- First posted
- 2004-12-09
- Last updated
- 2014-05-28
- Results first posted
- 2013-12-19
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Tumor Major Response Rate (Including Stable Disease) as Measured by RECIST Criteria | From start of treatment to 8 weeks |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Tumor Major Response Rate (Including Stable Disease) as Measured by RECIST Criteria | From start of treatment to 8 weeks | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Tumor Major Response Rate (Including Stable Disease) as Measured by RECIST Criteria | Treatment (Romidepsin) | Stable Disease | 10 | participants | |
| Tumor Major Response Rate (Including Stable Disease) as Measured by RECIST Criteria | Treatment (Romidepsin) | Progression of Disease | 1 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment (Romidepsin) | 20 | |
| Overall Study | COMPLETED | Treatment (Romidepsin) | 1 | |
| Overall Study | NOT COMPLETED | Treatment (Romidepsin) | 19 |
Source ClinicalTrials.gov
Adverse events37
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ALT, SGPT | Investigations | Treatment (Romidepsin) | 2 | 20 | 2 |
| other | Hypoalbuminemia | Metabolism and nutrition disorders | Treatment (Romidepsin) | 1 | 20 | 1 |
| other | Hypocalcemia | Metabolism and nutrition disorders | Treatment (Romidepsin) | 2 | 20 | 2 |
| other | Constipation | Gastrointestinal disorders | Treatment (Romidepsin) | 2 | 20 | 2 |
| other | Diarrhea | Gastrointestinal disorders | Treatment (Romidepsin) | 1 | 20 | 1 |
| other | Fatigue | General disorders | Treatment (Romidepsin) | 7 | 20 | 7 |
| other | Hyperglycemia | Metabolism and nutrition disorders | Treatment (Romidepsin) | 5 | 20 | 5 |
| other | Hemoglobin decrease | Blood and lymphatic system disorders | Treatment (Romidepsin) | 2 | 20 | 2 |
| other | White blood cell decrease | Investigations | Treatment (Romidepsin) | 3 | 20 | 3 |
| other | Nausea | Gastrointestinal disorders | Treatment (Romidepsin) | 2 | 20 | 2 |
1 to 10 of 37Source ClinicalTrials.gov
See all 37 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment (Romidepsin) | ||
| Total, other adverse events | Treatment (Romidepsin) | 16 | 20 |
| Total, serious adverse events | Treatment (Romidepsin) | 12 | 20 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00098813
GET https://conductscience.org/api/trials/v1/NCT00098813/events?page=2